NKGen Biotech (NKGN) Competitors $0.16 +0.00 (+0.50%) As of 03:40 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock NKGN vs. QTTB, RLYB, LEXX, LGVN, DARE, DRRX, TENX, ENLV, CDIO, and PASGShould you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Q32 Bio (QTTB), Rallybio (RLYB), Lexaria Bioscience (LEXX), Longeveron (LGVN), Daré Bioscience (DARE), DURECT (DRRX), Tenax Therapeutics (TENX), Enlivex Therapeutics (ENLV), Cardio Diagnostics (CDIO), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. NKGen Biotech vs. Q32 Bio Rallybio Lexaria Bioscience Longeveron Daré Bioscience DURECT Tenax Therapeutics Enlivex Therapeutics Cardio Diagnostics Passage Bio NKGen Biotech (NYSE:NKGN) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Which has preferable earnings & valuation, NKGN or QTTB? NKGen Biotech has higher revenue and earnings than Q32 Bio. Q32 Bio is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNKGen Biotech$80K97.76-$82.94M-$2.45-0.07Q32 Bio-$6.65M-3.61-$112.96M-$10.37-0.19 Do insiders & institutionals have more ownership in NKGN or QTTB? 76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 16.1% of Q32 Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in NKGN or QTTB? Q32 Bio received 12 more outperform votes than NKGen Biotech when rated by MarketBeat users. CompanyUnderperformOutperformNKGen BiotechN/AN/AQ32 BioOutperform Votes1263.16% Underperform Votes736.84% Does the media favor NKGN or QTTB? In the previous week, NKGen Biotech had 2 more articles in the media than Q32 Bio. MarketBeat recorded 3 mentions for NKGen Biotech and 1 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.87 beat NKGen Biotech's score of 0.00 indicating that Q32 Bio is being referred to more favorably in the news media. Company Overall Sentiment NKGen Biotech Neutral Q32 Bio Very Positive Do analysts recommend NKGN or QTTB? Q32 Bio has a consensus price target of $24.71, indicating a potential upside of 1,154.53%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts clearly believe Q32 Bio is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more risk and volatility, NKGN or QTTB? NKGen Biotech has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.27, suggesting that its share price is 127% less volatile than the S&P 500. Is NKGN or QTTB more profitable? NKGen Biotech's return on equity of 0.00% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets NKGen BiotechN/A N/A -479.36% Q32 Bio N/A -146.18%-54.49% SummaryNKGen Biotech beats Q32 Bio on 9 of the 16 factors compared between the two stocks. Remove Ads Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKGN vs. The Competition Export to ExcelMetricNKGen BiotechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$7.82M$3.03B$5.63B$19.63BDividend YieldN/A1.54%4.56%3.74%P/E Ratio-0.0329.2924.5333.66Price / Sales97.76437.38380.0527.64Price / CashN/A168.6838.1617.54Price / Book-0.063.956.954.59Net Income-$82.94M-$71.95M$3.20B$1.02B7 Day Performance8.75%-4.60%-2.28%-0.31%1 Month Performance-67.49%-9.37%3.09%-2.15%1 Year Performance-90.33%-25.70%11.26%4.80% NKGen Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKGNNKGen BiotechN/A$0.16+0.5%N/A-91.7%$7.23M$80,000.00-0.03N/AQTTBQ32 Bio2.6209 of 5 stars$2.19+9.5%$24.71+1,028.5%N/A$26.71M$-6,651,000.00-0.1539Positive NewsRLYBRallybio2.6613 of 5 stars$0.64+1.6%$9.75+1,418.2%-56.6%$26.64M$636,000.00-0.4040LEXXLexaria Bioscience3.2167 of 5 stars$1.47+8.7%$7.00+377.2%-52.6%$25.75M$496,923.00-2.937Positive NewsLGVNLongeveron2.5411 of 5 stars$1.72+1.8%$8.67+403.9%-50.1%$25.68M$2.39M-0.2720Short Interest ↑Gap UpDAREDaré Bioscience1.6264 of 5 stars$2.88flat$24.00+733.3%-51.8%$25.06M$1.88M-4.8830Short Interest ↑Positive NewsDRRXDURECT2.7147 of 5 stars$0.80-6.9%$5.00+524.2%-36.5%$24.87M$8.59M-1.3180Earnings ReportAnalyst ForecastNews CoverageTENXTenax Therapeutics1.8836 of 5 stars$6.23-2.8%$18.00+188.9%+63.9%$24.70MN/A0.009Earnings ReportAnalyst RevisionNews CoverageGap UpENLVEnlivex Therapeutics2.9903 of 5 stars$1.15-5.7%$9.50+726.1%-73.1%$24.62MN/A-1.1770Analyst ForecastAnalyst RevisionPositive NewsCDIOCardio Diagnostics2.8978 of 5 stars$0.46+9.1%$2.00+332.2%-68.3%$24.13M$35,688.000.001Short Interest ↓News CoverageGap UpPASGPassage Bio3.4963 of 5 stars$0.39+0.3%$7.50+1,838.0%-63.8%$24.05MN/A-0.33130Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Q32 Bio Alternatives Rallybio Alternatives Lexaria Bioscience Alternatives Longeveron Alternatives Daré Bioscience Alternatives DURECT Alternatives Tenax Therapeutics Alternatives Enlivex Therapeutics Alternatives Cardio Diagnostics Alternatives Passage Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NKGN) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
